TScan Therapeutics Inc (TCRX)
8.99
+0.98
(+12.23%)
USD |
NASDAQ |
May 14, 16:00
8.98
-0.01
(-0.11%)
After-Hours: 20:00
TScan Therapeutics Profit Margin (Quarterly): -5.33K% for March 31, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -5.33K% |
| December 31, 2023 | -272.0% |
| September 30, 2023 | -591.6% |
| June 30, 2023 | -763.8% |
| March 31, 2023 | -331.7% |
| December 31, 2022 | -604.9% |
| September 30, 2022 | -483.1% |
| June 30, 2022 | -372.2% |
| Date | Value |
|---|---|
| March 31, 2022 | -534.8% |
| December 31, 2021 | -497.5% |
| September 30, 2021 | -656.7% |
| June 30, 2021 | -374.8% |
| March 31, 2021 | -390.3% |
| December 31, 2020 | -982.0% |
| September 30, 2020 | -2.47K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-5.33K%
Minimum
Mar 2024
-272.0%
Maximum
Dec 2023
-976.9%
Average
-534.8%
Median
Mar 2022
Profit Margin (Quarterly) Benchmarks
| AnaptysBio Inc | -612.0% |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | -19.35K% |
| IGC Pharma Inc | -2.74K% |
| NovaBay Pharmaceuticals Inc | -122.2% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -68.03% |
| Return on Assets | -37.38% |
| Return on Invested Capital | -56.22% |
| Operating Margin (Quarterly) | -5.54K% |
| Return on Net Operating Assets | -115.6% |